Surjeet Singh, MD
Ophthalmology · Las Vegas, NVNPI 1013114628
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,886 and has fallen 75.2% since, to $468 in 2025.
Across 186 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson Surgical Vision, Inc.$755
- Ivantis, Inc$693
- Sight Sciences, Inc.$534
- plus $3K from 18 others
What the payments were for
- Food & beverage$8,408100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 30 | $1,459 |
| Alcon | 22 | $1,186 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $1,037 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $755 |
| Ivantis, Inc | 16 | $693 |
| Sight Sciences, Inc. | 7 | $534 |
| Bausch & Lomb Americas Inc. | 20 | $530 |
| NEW World Medical,inc. | 2 | $444 |
| Sun Pharmaceutical Industries Inc. | 11 | $325 |
| Rxsight Inc | 9 | $319 |
| AbbVie(2 entities) | 12 | $192 |
| Eyepoint US, Inc. | 4 | $184 |
| Astellas Pharma US Inc | 1 | $138 |
| Biotissue Holdings Inc. | 4 | $135 |
| Mallinckrodt Enterprises LLC | 2 | $132 |
| Amgen(2 entities) | 4 | $76 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Kala Pharmaceuticals, Inc. | 2 | $45 |
| Oyster Point Pharma, Inc. | 2 | $39 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $33 |
| Novartis | 2 | $27 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Lensar, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$698
- Photrexa$407
- iStent inject Trabecular Micro-Bypass Stent System$372
- VYZULTA$358
- OMNI(R) SURGICAL SYSTEM (US)$307
- Clareon$304
- STELLARIS$303
- Hydrus$287
- ENVISTA$241
- Tecnis Multifocal Family of 1-piece IOLS$237
- Tecnis Symfony IOL$237
- Tecnis Simplicity$235
- enVista MX60 IOL$232
- Kahook Dual Blade$200
- Streamline Surgical System$200
- Ahmed Glaucoma Valve$200
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$178
- iDoseTR$177
- iDose$169
- DEXYCU$163
How this compares
$8,408 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 126 | $169,560 |
| IlevroNepafenac | 253 | $92,480 |
| ProlensaBromfenac Sodium | 184 | $63,382 |
| Prednisolone Acetate | 1,541 | $60,157 |
| LumiganBimatoprost | 64 | $30,948 |
| MoxifloxacinMoxifloxacin Hcl | 1,099 | $24,434 |
| XiidraLifitegrast | 24 | $22,865 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $17,401 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $14,532 |
| Latanoprost | 1,406 | $12,190 |
| Brimonidine Tartrate | 278 | $11,309 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $9,497 |
| Cyclosporine | 17 | $7,189 |
| Travoprost | 29 | $5,242 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $5,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $192 | $220,061246 claims |
| NovartisIlevro | $27 | $92,480253 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,037 | $63,382184 claims |
| Bausch & Lomb Americas Inc.Xiidra | $530 | $22,86524 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $38 | $17,40133 claims |
| AlconSimbrinza | $1,186 | $9,49735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Las Vegas
- Eva LiangLas Vegas$496K
- Steven LeibowitzLas Vegas$147K
- Wonchon LinLas Vegas$43K
- Ravindranath ReddyLas Vegas$30K
- Emily SchorrLas Vegas$17K
- Frank LeeLas Vegas$12K
- Tigran KostanyanLas Vegas$11K
- Tushina ReddyLas Vegas$11K
- Kent WellishLas Vegas$10K
- Eissa HannaLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.